AstraZeneca Pulls Motavizumab Prophylaxis BLA, But Phase II Trial Continues
This article was originally published in The Pink Sheet Daily
Executive Summary
Company takes a $445 million charge after apparently opting not to undertake an additional trial that FDA had requested following an advisory committee, but the firm is still pursuing a possible claim for treatment of respiratory syncytial virus disease.
You may also be interested in...
Epidemiology First: MedImmune Moving Ahead With Preventive Antibodies, But Needs More HAP Data
The biotech’s senior VP for infectious disease and vaccine R&D says prevention must be a part of fighting antimicrobial resistance, but moving the new approach into advanced trials first requires getting a handle on the incidence of hospital-acquired pneumonia in intensive care patients.
MedImmune/Abbott Dispute Over Motavizumab Involves $50 Mil. In Synagis Payments
MedImmune sues Abbott following its decision not to seek approval of the second-generation respiratory syncytial virus treatment outside the U.S.
MedImmune/Abbott Dispute Over Motavizumab Involves $50 Mil. In Synagis Payments
MedImmune sues Abbott following its decision not to seek approval of the second-generation respiratory syncytial virus treatment outside the U.S.